

Building A Safer Isotope

BC Scientists Solve Health-Care Dilemma

University of British Columbia





Hundreds of thousands of people around the globe have benefited from something they've never heard of: technetium-99m. Tc-99m, as it's known in scientific circles, is the world's most-popular diagnostic imaging isotope.

When injected into a patient, isotopes allow medical specialists to closely examine target areas noninvasively, with special equipment. Tc-99m is used in more than 80 percent of all nuclear medicine procedures—some 30 million times a year—to diagnose cancer, Parkinson's and other serious conditions.

Historically, valuable medical isotopes like Tc-99m have been produced worldwide at nuclear reactors such as Ontario's Chalk River. But a series of outages in recent years at key, often aging reactors led to a shortage of Tc-99m and significant health-care disruptions.

The Chalk River reactor shut down in March 2018, after more than 60 years online, leaving
Canada without a major source of medical isotopes. Chalk River had produced 40 percent of the

world's supply of Tc-99m.

Since 2009 the search has been on to bypass nuclear reactors and develop new ways to produce radioisotopes. TRIUMF, a renowned subatomic physics laboratory based at the University of British Columbia, headed a partnership that eventually came up with breakthrough technology.

The method uses cyclotrons, a type of particle accelerator found worldwide in hospitals, clinics and radiopharmacies that provide medical imaging. This means that

Tc-99m and other radioisotopes such as copper-64 and gallium-68 can now be produced locally as needed. And by employing nonradioactive elements, the cyclotron process eliminates the use of enriched uranium and results in no long-term radioactive waste.

This technology is "a viable alternative that allows for a safe, reliable and environmentally sound supply of a critical medical isotope," said Paul Schaffer, CEO of ARTMS Products Inc., a Vancouver-based company launched by the TRIUMF consortium to market the technology worldwide.

ARTMS, recipient of the BC Tech Association's 2017 award for "Most Promising Pre-Commercial Technology," has now taken a big next step on the world stage, partnering with U.K.-based Alliance Medical, the leading independent provider of diagnostic imaging services across Europe.

This story was originally published in 2018.

To see available technologies from research institutions, click here to visit the AUTM Innovation Marketplace.

Share your story at autm.net/betterworldproject

#betterworldproject